QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study

QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study is a phase 2, interventional study registered as NCT07649473 by Fujian Medical University, with a registry enrolment figure of 30 participants, started 2026-08-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: QL1706 (Iparomlimab/Tuvonralimab). Conditions listed: Colon Cancer; Synchronous Liver Metastases. Primary outcome: Rate of R0 Resection and Complete Ablation. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed colon adenocarcinoma, with pathologically or radiographically verified liver-only metastases". Sites: China. No results are recorded here; the registry entry is the source.